The doubling of the price target by a reputable analyst like Serge Belanger from Needham is a strong endorsement of Arcutis Biotherapeutics' future prospects. This significant increase in the price target is likely to instill confidence in investors about the company's potential for growth, possibly leading to a short-term increase in the stock price.